Targeted cancer therapy with a 2-deoxyglucose-based adriamycin complex
| Autor: | Changli Du, Siwen Li, Sisi Cui, Guangji Wang, Wei R. Chen, Shunan Wan, Junmei Tian, Zhiyu Qian, Yueqing Gu, Jie Cao |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Cancer Research
Cell Survival Chemistry Pharmaceutical Succinic Acid Mice Nude Pharmacology Deoxyglucose Mice In vivo Cell Line Tumor Neoplasms medicine Animals Humans MTT assay Cardiotoxicity Glucose Transporter Type 1 Antibiotics Antineoplastic Microscopy Confocal biology Molecular Structure Chemistry Cancer Hep G2 Cells medicine.disease Xenograft Model Antitumor Assays Tumor Burden Oncology Models Chemical Doxorubicin Toxicity Cancer cell biology.protein MCF-7 Cells GLUT1 Quercetin |
| Zdroj: | Cancer research. 73(4) |
| ISSN: | 1538-7445 |
| Popis: | Adriamycin (ADM) has been effective against many types of solid tumors in clinical applications. However, its use is limited because of systemic toxicities, primarily cardiotoxicity, and multidrug resistance. In this study, a new active receptor-mediated complex, ADM conjugated with 2-amino-2-deoxy-d-glucose and succinic acid (2DG–SUC–ADM), was designed to target tumor cells through glucose transporter 1 (GLUT1). MTT assay and confocal images showed that the complex had better inhibition rate to tumor cells and low toxicity to normal cells. Most importantly, the complex displayed a potential to reverse overcome multidrug resistance in cancer cells, with more complex transported into the nucleus of tumor cells. Our in vivo experiments also showed that this new complex could significantly decrease organ toxicity and enhance the antitumor efficacy compared with free ADM, indicating a promising drug of 2DG–SUC–ADM for targeted cancer therapy. Cancer Res; 73(4); 1362–73. ©2012 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|